
Edgewise management will be doing a fireside chat presentation at Guggenheim Securities 3rd Annual Healthcare Innovation Conference at 8:00am ET. Read the full press release: investors.edgewisetx.com/new…
✓Biopharmaceutical company focused on therapeutics for cardiovascular diseases.

Edgewise management will be doing a fireside chat presentation at Guggenheim Securities 3rd Annual Healthcare Innovation Conference at 8:00am ET. Read the full press release: investors.edgewisetx.com/new…

Today we announced a productive End-of-Phase 2 meeting with FDA for EDG-7500 in symptomatic hypertrophic cardiomyopathy (HCM). The Phase 3 protocol features tolerability-based dose escalation without safety echo monitoring. See the full press release here: investors.edgewisetx.com/new…

Today we announced Q3 2026 financial results and recent business highlights. The results are available on our website: investors.edgewisetx.com/new…

At the @American_Heart’s Annual Scientific Sessions, we’ll present on EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction. Stop by booth #2812 to meet our team!

We are a proud supporter of the International HCM Summit. Leading HCM experts will join Edgewise's Craig Emter in a session that explores investigational molecule, EDG-7500, as a potential treatment for HCM. Learn more: hcmsummit.org/2026-edgewise

We're excited to share the first data from our program in heart failure, EDG-15400, which we recently announced has now entered Phase 2. Find us at the Heart Failure Society of America’s 2026 Annual Scientific Meeting to discuss these findings.

First patient dosed in the Phase 2 EQUINOX-HFpEF study evaluating our investigational cardiac sarcomere modulator, EDG-15400! We'll present Phase 1 data of EDG-15400 in healthy adults & the EQUINOX-HFpEF study design at @HFSA's Scientific Meeting. investors.edgewisetx.com/new…

We’re attending Targeted Therapies and Emerging Options for Cardiomyopathies, a 3-day conference in Florence dedicated to cardiomyopathy care and research. Come visit our table to meet the team and learn about our ongoing work in cardiovascular disease.

Today, we shared new preclinical research highlighting the differentiated mechanism of action of EDG-7500, our first-in-class cardiac sarcomere modulator targeting the regulatory light chain. Press release and full publication: investors.edgewisetx.com/new… edgewisetx.com/science/poste…

Find us at the 2026 @escardio Congress, booth K730 – Hall A2! Dr. Anjali T. Owens, M.D., will present our data during the session “Transforming the heart: novel therapies for myocardial disease and heart failure.” Read the press release: investors.edgewisetx.com/new…

Today we announced Q2 2026 financial results and recent business highlights. The results are available on our website: investors.edgewisetx.com/new…

Hypertrophic cardiomyopathy (HCM) is a chronic heart disease characterized by thickening of the heart muscle. Edgewise is dedicated to improving the lives of people with serious cardiovascular diseases, including HCM. Visit edgewisetx.com/disease-areas….

Today we announced Servier's acquisition of our muscular dystrophy program, including sevasemten. Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases. Read more: investors.edgewisetx.com/new…

We're headed to the International Congress on Neuromuscular Diseases in Florence, Italy! Our team is looking forward to connecting with leaders in the neuromuscular space to advance the understanding, diagnosis, and care landscape.

Our team is looking forward to sharing the rationale, study design & baseline characteristics on our GRAND CANYON pivotal cohort (Poster A-26-20290) at the 12th Congress of the European Academy of Neurology (EAN)! Learn more: ean.org/congress2026

Find us at the 2026 BIO International Convention. VP of Patient Advocacy, Abby Bronson, will be speaking on strategies to integrate the patient perspective from clinical discovery to commercialization. Register for the session: tinyurl.com/4bnajkde #BIO2026